CoChat

Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

Open access
Feinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., on behalf of the Liraglutide Dose‐Response Study Group · 2005 · Diabetic Medicine
Cited by 151

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims Liraglutide (NN2211) is a long‐acting GLP‐1 analogue, with a pharmacokinetic profile suitable for once‐daily administration. This multicentre, double‐blind, parallel‐group, double‐dummy study explored the dose–response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes. Methods Subjects (BMI 27–42 kg/m 2) with Type 2 diabetes who were previously treated with an OAD (oral anti‐diabetic drug) monotherapy (69% with metformin), and had HbA 1c ≤ 10% were enrolled. After a 4‐week metformin run‐in period, 210 subjects (27–73 years, 60% female) were randomised to receive liraglutide (0.045–0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks. Results Mean baseline values for the six treatment groups ranged from 6.8 to 7.5% for HbA 1c, and 8.06–9.44 mmol/l (145–170 mg/dl) for fasting plasma glucose. After 12‐week treatment, a weight change of −0.05 to −1.9% was observed for the six treatment groups. Mean HbA 1c changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively. No significant differences in HbA 1c were observed between liraglutide and metformin groups at the three highest liraglutide dose levels (0.45, 0.6 and 0.75 mg). The lowest two liraglutide doses (0.045 mg and 0.225 mg) were not sufficient to maintain the fasting plasma glucose values achieved by metformin. No major hypoglycaemic episodes were reported. Episodes of nausea and/or vomiting were reported by 11 patients (6.3%) receiving liraglutide and three (8.8%) receiving metformin. Conclusions Once‐daily liraglutide improved glycaemic control and weight, in a comparable degree to metformin. Liraglutide appeared to be safe and generally well tolerated. Higher doses of liraglutide merit study in future clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01567.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 151

Metadata

Authors
Feinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., & on behalf of the Liraglutide Dose‐Response Study Group
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-07-13
Volume
22
Issue
8
Pages
1016-1023
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2023462541
Cited by
151
References
7
FWCI
12.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01567.x
The paper
Feinglos, M. N., Saad, M. F., Pi‐Sunyer, F. X., An, B., Santiago, O., & on behalf of the Liraglutide Dose‐Response Study Group. (2005). Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01567.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.